Location of Repository

The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre

By Terri Patricia McVeigh, Lauren M. Hughes, Nicola Miller, Margaret Sheehan, Maccon Keane, Karl J. Sweeney and Michael J. Kerin

Abstract

A cohort study was undertaken, including consecutive patients with early node-\ud negative, ER-positive breast cancer diagnosed between 2006 and May 2013, including a\ud period of prospective clinical trial (Trial Assigning Individualised Options for Treatment\ud (TAILORx)) recruitment. Data were collected regarding patient demographics, tumour clinic-\ud o-pathological features, Oncotype DX use and recurrence score and chemotherapy use. All\ud therapeutic decisions were made following multidisciplinary discussion, with adherence to\ud guidelines and consideration of trial protocol and Oncotype DX recurrence scores

Topics: BREAST CANCER
Publisher: European Journal of Cancer
Year: 2014
DOI identifier: 10.1016/j.ejca.2014.08.002
OAI identifier: oai:www.lenus.ie:10147/326382

Suggested articles

Preview


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.